Ann: Appendix 4D - Half Year Accounts - 31 December 2020, page-5

The activities for 2021 include the creation of a Master Cell Bank based on the slected stable cell line, then large scale
manufacture of clinical grade PAT-DX1 for the final preclinical studies that are required to complete PAT-DX1’s regulatory
dossier. Other ongoing activities include the further development of nanoparticle delivery opportunities, ongoing efforts to
build our understanding of the biology of deoxymab antibodies, new intellectual property patent filings and a focus on
establishment of collaborations and alliances.

Keep ticking the boxes and by Xmas we will be looking oh so much better..............expecting corporate activity to start amping up after each box in the list is ticked

GLTAH